CA2119562A1 - Method and compositions for the treatment of cerebral palsy - Google Patents

Method and compositions for the treatment of cerebral palsy

Info

Publication number
CA2119562A1
CA2119562A1 CA002119562A CA2119562A CA2119562A1 CA 2119562 A1 CA2119562 A1 CA 2119562A1 CA 002119562 A CA002119562 A CA 002119562A CA 2119562 A CA2119562 A CA 2119562A CA 2119562 A1 CA2119562 A1 CA 2119562A1
Authority
CA
Canada
Prior art keywords
treatment
cerebral palsy
compositions
juvenile patients
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002119562A
Other languages
French (fr)
Other versions
CA2119562C (en
Inventor
Herbert K. Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Herbert K. Graham
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10701881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2119562(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Herbert K. Graham, Allergan, Inc. filed Critical Herbert K. Graham
Publication of CA2119562A1 publication Critical patent/CA2119562A1/en
Application granted granted Critical
Publication of CA2119562C publication Critical patent/CA2119562C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.
CA002119562A 1991-09-24 1992-09-16 Method and compositions for the treatment of cerebral palsy Expired - Lifetime CA2119562C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919120306A GB9120306D0 (en) 1991-09-24 1991-09-24 Method and compositions for the treatment of cerebral palsy
GB9120306.7 1991-09-24
PCT/GB1992/001697 WO1993005800A1 (en) 1991-09-24 1992-09-16 Method and compositions for the treatment of cerebral palsy

Publications (2)

Publication Number Publication Date
CA2119562A1 true CA2119562A1 (en) 1993-04-01
CA2119562C CA2119562C (en) 2005-02-15

Family

ID=10701881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002119562A Expired - Lifetime CA2119562C (en) 1991-09-24 1992-09-16 Method and compositions for the treatment of cerebral palsy

Country Status (13)

Country Link
US (7) US6395277B1 (en)
EP (1) EP0605501B2 (en)
JP (2) JP3535872B2 (en)
AT (1) ATE178799T1 (en)
AU (1) AU666334B2 (en)
CA (1) CA2119562C (en)
DE (1) DE69228938T3 (en)
DK (1) DK0605501T5 (en)
ES (1) ES2131073T5 (en)
GB (1) GB9120306D0 (en)
GR (1) GR3030418T3 (en)
NO (2) NO312747B1 (en)
WO (1) WO1993005800A1 (en)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP0702561B1 (en) * 1993-06-10 2002-01-09 Allergan, Inc. Treatment of neuromuscular disorders and conditions with botulinum serotyp e
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69434610T2 (en) * 1993-12-28 2008-11-27 Allergan, Inc., Irvine Use of the neurotoxic component of botulinum toxin for the treatment of muscle spasms
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (en) * 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． How to reduce headaches
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DE69535530D1 (en) * 1994-10-24 2007-08-16 Ophidian Pharm Inc Vaccine and antitoxins for the treatment and prevention of C. difficile diseases
EP1053014A4 (en) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
EP1365800B1 (en) * 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
DE10035156A1 (en) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh New protein complex containing complex protein from botulinum toxin, useful for oral delivery of therapeutic polypeptide or low molecular weight pharmaceutical
DK2364734T3 (en) * 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
ITUD20010002A1 (en) * 2001-01-05 2002-07-05 Univ Degli Studi Udine USE OF BOTULIN TOXIN FOR THE SOLUTION OF JOINT PATHOLOGIES, IN PARTICULAR OF COXARTROSIS, EPICONDYLITIS AND PATHOLUS
JP4707254B2 (en) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 Granular composition and method for producing the same
AU2002348370B8 (en) 2001-11-15 2008-05-01 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1491205A4 (en) * 2002-03-29 2007-04-25 Chemo Sero Therapeut Res Inst Remedy for hypermyotonia
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
MXPA05006690A (en) * 2002-12-20 2006-02-17 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions.
MXPA05009425A (en) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin.
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
PT2656859E (en) * 2004-03-03 2016-02-24 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050206225A1 (en) * 2004-03-18 2005-09-22 Ford Global Technologies, Llc Method and apparatus for predicting the position of a trailer relative to a vehicle
MXPA06012962A (en) * 2004-05-07 2007-06-12 Phytotox Ltd Methods of treating wounds with gonyautoxins.
BRPI0510760A (en) * 2004-05-07 2007-11-20 Phytotox Ltd method for administering to a patient a composition, topical composition, and patch
US20080045889A1 (en) * 2004-07-21 2008-02-21 Gerondale Scott J Botoxo Needle Injector
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
ATE507236T1 (en) 2005-03-03 2011-05-15 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL ADMINISTRATION OF AN OLIGOPEPTIDE
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2008010788A2 (en) 2005-07-18 2008-01-24 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
US8568740B2 (en) * 2005-11-17 2013-10-29 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
EP3144013B1 (en) 2005-12-01 2018-11-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
AR061669A1 (en) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
JP5292304B2 (en) 2006-12-01 2013-09-18 アンテリオス， インコーポレイテッド Peptide nanoparticles and uses thereof
CN101848702B (en) 2006-12-01 2013-07-17 安特里奥公司 Amphiphilic entity nanoparticles
US20100093639A1 (en) * 2006-12-29 2010-04-15 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
MX2009007068A (en) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat.
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
CN102014779B (en) 2008-05-09 2014-10-22 赫莱拉公司 Systems, assemblies, and methods for treating a bronchial tree
BRPI0914630A2 (en) * 2008-06-26 2019-09-24 Anterios Inc dermal release
JP5752598B2 (en) 2008-09-11 2015-07-22 アイ．ビー．アール． イスラエリ バイオテクノロジー リサーチ リミテッド Leukoyumu bulb extract and its use
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
JP4697289B2 (en) 2008-11-05 2011-06-08 ソニー株式会社 Imaging apparatus and display control method for imaging apparatus
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
CN112089394A (en) 2009-10-27 2020-12-18 努瓦拉公司 Delivery device with coolable energy emitting assembly
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
WO2011060200A1 (en) 2009-11-11 2011-05-19 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
WO2013009625A1 (en) 2011-07-08 2013-01-17 Allergan, Inc. Method for treatment of autonomic nervous system disorders
CN103813802A (en) 2011-07-14 2014-05-21 阿勒根公司 Methods for treatment of incontinence associated with sexual activity
CN103702681A (en) 2011-07-20 2014-04-02 阿勒根公司 Botulinum toxins for use in a method for treatment of adipose deposits
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
ES2807356T3 (en) 2012-09-25 2021-02-22 Haldor Topsoe As Steam reforming catalyst and process for making the same
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2017007577A1 (en) 2015-07-08 2017-01-12 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment
CN110198703A (en) 2016-11-21 2019-09-03 艾里奥治疗公司 The transdermal delivery of big reagent
WO2019226858A1 (en) * 2018-05-24 2019-11-28 Children's Hospital Medical Center Compositions and methods for the treatment of muscle contractures
US20230365957A1 (en) * 2020-10-07 2023-11-16 Pro-Tox Inc. Vacuum drying method for botulinum toxin

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4234566A (en) * 1979-06-29 1980-11-18 Packman Elias W Antihistamine and methods for use thereof
US4720494A (en) * 1984-11-05 1988-01-19 The Gillette Company Anticholinergic eucatropine esters and antiperspirant use thereof
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
EP0262396A3 (en) 1986-09-20 1989-08-23 Heinz Dipl.-Ing. Hölter Process for the preparation of calcium sulphate dihydrate during flue-gas desulfurization
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4935969A (en) * 1987-12-02 1990-06-26 Farnsworth Orin J Method and device for the controlled disposal of human waste
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5056291A (en) * 1989-10-19 1991-10-15 Skilland Engineering, Ltd. Modular system for space frame structures
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (en) 1992-06-19 2000-04-21 Montpellier Chirurgie TOTAL KNEE PROSTHESIS.
AU4646393A (en) 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
JPH06192296A (en) 1992-10-28 1994-07-12 Chiba Pref Gov Production of crystal a type botulinus toxin as medicine for therapy
JP4381477B2 (en) 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド Method for treating fascial pain syndrome
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
AU683275B2 (en) 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP0702561B1 (en) 1993-06-10 2002-01-09 Allergan, Inc. Treatment of neuromuscular disorders and conditions with botulinum serotyp e
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
DE69434610T2 (en) 1993-12-28 2008-11-27 Allergan, Inc., Irvine Use of the neurotoxic component of botulinum toxin for the treatment of muscle spasms
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (en) 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． How to reduce headaches
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
TWI243265B (en) 2002-02-27 2005-11-11 Chi Mei Optoelectronics Corp Method for forming a reflection-type light diffuser

Also Published As

Publication number Publication date
NO941065D0 (en) 1994-03-23
EP0605501B2 (en) 2006-11-29
JP3535872B2 (en) 2004-06-07
DK0605501T5 (en) 2007-02-26
NO941065L (en) 1994-03-23
US20050142150A1 (en) 2005-06-30
ES2131073T5 (en) 2007-06-16
US20080206224A1 (en) 2008-08-28
DE69228938D1 (en) 1999-05-20
NO312747B1 (en) 2002-07-01
US20050112146A1 (en) 2005-05-26
JPH06510779A (en) 1994-12-01
GR3030418T3 (en) 1999-09-30
CA2119562C (en) 2005-02-15
NO20013727L (en) 1994-03-23
AU666334B2 (en) 1996-02-08
EP0605501A1 (en) 1994-07-13
US7378389B2 (en) 2008-05-27
DE69228938T3 (en) 2008-01-03
US6448231B2 (en) 2002-09-10
US20010046962A1 (en) 2001-11-29
WO1993005800A1 (en) 1993-04-01
NO20013727D0 (en) 2001-07-30
US6395277B1 (en) 2002-05-28
EP0605501B1 (en) 1999-04-14
DE69228938T2 (en) 1999-09-23
ES2131073T3 (en) 1999-07-16
AU2566492A (en) 1993-04-27
JP2002097154A (en) 2002-04-02
US20070224221A1 (en) 2007-09-27
US20020142010A1 (en) 2002-10-03
NO324159B1 (en) 2007-09-03
DK0605501T3 (en) 1999-10-25
ATE178799T1 (en) 1999-04-15
GB9120306D0 (en) 1991-11-06

Similar Documents

Publication Publication Date Title
CA2119562A1 (en) Method and compositions for the treatment of cerebral palsy
EP0853121A3 (en) Human DNase
KR0145958B1 (en) Antibacterial agents
AU549102B2 (en) Aromatic heterocyclic esters of steroids
AU6701890A (en) Process for the production of biologically active protein
AU563748B2 (en) Quinolone carboxylic acids
DE59508891D1 (en) SKIN CARE PRODUCTS
EP1421948A3 (en) Use of botulinum toxins for treating sweating in humans
EP1099445A3 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
EP0251717A3 (en) Chemically modified islet-activating protein
EP0142426A3 (en) Ophthalmic formulation containing norfloxacin and related antibiotics
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
HK1010983A1 (en) Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
DK0500773T3 (en) Non-glycosylated FGF-4 and preparations containing this
GB2259647B (en) Medicaments for treating gastrointestinal disorders
EP0593176A3 (en) Pharmaceutical compositions containing botulinum toxin and method of preparation.
WO1996022305A3 (en) Modified peptides
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
CA2079171A1 (en) Cyclohexapeptidyl propanolamine compounds
AU7792294A (en) Antibacterial composition containing multimeric alpha-lactalbumin
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
EP0373771A3 (en) New pharmaceutical uses for cystatins
IE870577L (en) Topical amide preparation
DE69609614D1 (en) INSECTICIDAL COMPOSITION CONTAINING DIATOME EARTH AND SILICON DIOXIDE

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry